Peer-reviewed veterinary case report
SDMA levels in cats with kidney injury and disease
By Loane, Samantha C et al.·Published in Journal of veterinary internal medicine·2022·Department of Veterinary Medicine, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of symmetric dimethylarginine in cats with acute kidney injury and chronic kidney disease.
- Species:
- cat
Plain-English summary
A group of cats with kidney issues were tested for a substance called symmetric dimethylarginine (SDMA) to see if it could help identify those with acute kidney injury (AKI) or chronic kidney disease (CKD). The study found that cats with AKI had significantly higher SDMA levels compared to healthy cats, suggesting that this test could be useful for diagnosing kidney problems in cats. The results showed a strong link between SDMA levels and kidney function, indicating that SDMA could be a helpful tool for veterinarians in assessing kidney health in cats.
People also search for: cat kidney disease symptoms · cat acute kidney injury treatment · elevated SDMA in cats
Abstract
BACKGROUND: Serum symmetric dimethylarginine (SDMA) concentrations are considered a biomarker for renal dysfunction in dogs and humans with acute kidney injury (AKI). No studies have assessed SDMA in cats with AKI. HYPOTHESIS/OBJECTIVES: SDMA correctly identifies cats with azotemic AKI. ANIMALS: Fifteen control cats, 22 with novel AKI, 13 with acute on chronic-AKI (AoC) and 19 with chronic kidney disease (CKD). METHODS: Retrospective study. Cats with azotemia (serum creatinine concentrations >1.7 mg/dL) were defined as having AKI or CKD based on history, clinical signs, clinicopathological findings and diagnostic imaging, and classified using the International Renal Interest Society (IRIS) grading/staging systems. Serum SDMA concentrations were compared between groups with nonparametric methods, and correlations assessed using Spearman's correlation coefficient. Data are presented as median [range]. RESULTS: SDMA concentrations were 11 (8-21) μg/dL, 36 (9-170)μg/dL, 33 (22-75) μg/dL and 25 (12-69) μg/dL in control, novel AKI, AoC and CKD cats. SDMA concentrations were significantly higher in cats with novel AKI (P < .001), AoC (P < .001) and CKD (P < .01) compared to controls. SDMA concentrations were significantly higher in cats with more advanced AKI (IRIS grade IV-V) compared to less severe AKI (IRIS grade II). Serum creatinine and SDMA concentrations had a significant correlation in cats with novel AKI (r = 0.826, n = 22; P < .001) and a significant correlation when all cats across all 4 groups were considered together (r = 0.837, n = 69; P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Serum SDMA concentrations are elevated in cats with established AKI (novel and AoC) and CKD, providing evidence for use of SDMA as a biomarker for AKI in cats.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/35903963/